Effect of rosuvastatin 5-20mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia.

Article Details

Citation

Copy to clipboard

Saito Y, Yamada N, Shirai K, Sasaki J, Ebihara Y, Yanase T, Fox JC

Effect of rosuvastatin 5-20mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia.

Atherosclerosis. 2007 Oct;194(2):505-11. Epub 2007 Jan 16.

PubMed ID

17223112 [ View in PubMed

]

Abstract

To evaluate the potential dose effect of rosuvastatin on triglyceride (TG) levels in Japanese hypertriglyceridemic patients, we randomized 154 patients with TG levels of >or=200 and <800 mg/dL to 8 weeks of treatment with rosuvastatin 5, 10 or 20mg once daily; bezafibrate 200mg twice daily; or placebo. Compared with placebo, TG was reduced by 30.1% with rosuvastatin 5mg, 30.1% with 10mg and 32.3% with 20mg (all p

DrugBank Data that Cites this Article

Pharmaco-metabolomics

Drug	Drug Groups	Metabolite	Change	Description
Rosuvastatin	Approved	Non-HDL cholesterol	decreased	Rosuvastatin decreases the level of Non-HDL cholesterol in the blood
Rosuvastatin	Approved	VLDL triglycerides	decreased	Rosuvastatin decreases the level of VLDL triglycerides in the blood
Rosuvastatin	Approved	Remnant-like particle cholesterol	decreased	Rosuvastatin decreases the level of Remnant-like particle cholesterol in the blood
Bezafibrate	Approved Investigational	Remnant-like particle cholesterol	decreased	Bezafibrate decreases the level of Remnant-like particle cholesterol in the blood
Rosuvastatin	Approved	Total cholesterol	decreased	Rosuvastatin decreases the level of Total cholesterol in the blood
Rosuvastatin	Approved	HDL cholesterol	increased	Rosuvastatin increases the level of HDL cholesterol in the blood
Rosuvastatin	Approved	Triglycerides	decreased	Rosuvastatin decreases the level of Triglycerides in the blood
Rosuvastatin	Approved	LDL cholesterol	decreased	Rosuvastatin decreases the level of LDL cholesterol in the blood